Biological and technical considerations regarding the removal of bacteriotoxins in sepsis with emphasis on toxic shock syndrome toxin 1

Shock

Volumn 37, Issue 3, 2012, Pages 247-252

  Brummelhuis, Walter J ^a   Joles, Jaap A ^a   Stam, Jord ^b   Verrips, C Theo ^b   Braam, Branko ^c,d  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

Author keywords

cameloid antibodies; hemofiltration; immunocapturing; plasmapheresis; Toxic shock syndrome

Indexed keywords

BACTERIAL TOXIN; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR NECROSIS FACTOR ALPHA;

BLOOD TRANSFUSION; HEMOFILTRATION; HUMAN; IMMUNOADSORPTION; IN VITRO STUDY; IN VIVO STUDY; LEUKAPHERESIS; NONHUMAN; PHYSICAL CHEMISTRY; PLASMAPHERESIS; REVIEW; SEPSIS;

BACTERIAL TOXINS; ENTEROTOXINS; HUMANS; PLASMAPHERESIS; SEPSIS; SUPERANTIGENS;

EID: 84857520379     PISSN: 10732322     EISSN: 15400514     Source Type: Journal    
DOI: 10.1097/SHK.0b013e3182429b38     Document Type: Review

References (61)

1. Sasse KC, Nauenberg E, Long A, Anton B, Tucker HJ, Hu TW: Long-term survival after intensive care unit admission with sepsis. Crit Care Med 23(6): 1040-1047, 1995.
2. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR: Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303-1310, 2001. (Pubitemid 32641789)
3. Bone RC: The pathogenesis of sepsis. Ann Intern Med 115(6):457-469, 1991.
4. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, Davies NA, Cooper CE, Singer M: Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360(9328):219-223, 2002. (Pubitemid 34804650)
5. Szabo C: Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 3(1):2-32, 1995.
6. Russell JA: Vasopressin and its copilot copeptin in sepsis and septic shock. Crit Care Med 37(2):749-750, 2009.
7. Weitzberg E, Lundberg JM, Rudehill A: Elevated plasma levels of endothelin in patients with sepsis syndrome. Circ Shock 33(4):222-227, 1991.
8. Wang H, Cheng B, Chen Q, Wu S, Lv C, Xie G, Jin Y, Fang X: Time course of plasma gelsolin concentrations during severe sepsis in critically ill surgical patients. Crit Care 12(4):R106, 2008.
9. Macarthur H, Westfall TC, Riley DP, Misko TP, Salvemini D: Inactivation of catecholamines by superoxide gives new insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 97(17):9753-9758, 2000. (Pubitemid 30650848)
10. Huet O, Cherreau C, Nicco C, Dupic L, Conti M, Borderie D, Pene F, Vicaut E, Benhamou D, Mira JP, et al.: Pivotal role of glutathione depletion in plasmainduced endothelial oxidative stress during sepsis. Crit Care Med 36(8): 2328-2334, 2008.
11. Dinges MM, Orwin PM, Schlievert PM: Exotoxins of Staphylococcus aureus. Clin Microbiol Rev 13(1):16-34, table of contents, 2000. (Pubitemid 30039341)
12. Fraser JD, Proft T: The bacterial superantigen and superantigen-like proteins. Immunol Rev 225:226-243, 2008.
13. Lappin E, Ferguson AJ: Gram-positive toxic shock syndromes. Lancet Infect Dis 9(5):281-290, 2009.
14. Schlievert PM, Tripp TJ, Peterson ML: Reemergence of staphylococcal toxic shock syndrome in MinneapolisYSt. Paul, Minnesota, during the 2000-2003 surveillance period. J Clin Microbiol 42(6):2875-2876, 2004. (Pubitemid 38747565)
15. Bengsch S, Boos KS, Nagel D, Seidel D, Inthorn D: Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23(6):494-500, 2005. (Pubitemid 40677420)
16. Bottoms G, Fessler J, Murphey E, Johnson M, Latshaw H, Mueller B, Clark W, Macias W: Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 5(2):149-154, 1996. (Pubitemid 126727645)
17. Sykora R, Chvojka J, Krouzecky A, Radej J, Kuncova J, Varnerova V, Karvunidis T, Novak I, Matejovic M: Coupled plasma filtration adsorption in experimental peritonitis-induced septic shock. Shock 31(5):473-480, 2009.
18. Vincent JL, Laterre PF, Cohen J, Burchardi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Marzo D, et al.: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23(5):400-405, 2005. (Pubitemid 40571661)
19. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al.: Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301(23):2445-2452, 2009.
20. Vincent JL: Sepsis: clearing the blood in sepsis. Nature reviews. Nephrology 5(10):559-560, 2009.
21. Larkin EA, Carman RJ, Krakauer T, Stiles BG: Staphylococcus aureus: the toxic presence of a pathogen extraordinaire. Curr Med Chem 16(30): 4003-4019, 2009.
22. Bannan J, Visvanathan K, Zabriskie JB: Structure and function of streptococcal and staphylococcal superantigens in septic shock. Infect Dis Clin North Am 13(2):387-396, ix, 1999. (Pubitemid 29248751)
23. Vergeront JM, Evenson ML, Crass BA, Davis JP, Bergdoll MS, Wand PJ, Noble JH, Petersen GK: Recovery of staphylococcal enterotoxin F from the breast milk of a woman with toxic-shock syndrome. J Infect Dis 146(4): 456-459, 1982. (Pubitemid 12004442)
24. Miwa K, Fukuyama M, Kunitomo T, Igarashi H: Rapid assay for detection of toxic shock syndrome toxin 1 from human sera. J Clin Microbiol 32(2): 539-542, 1994. (Pubitemid 24033931)
25. Azuma K, Koike K, Kobayashi T, Mochizuki T, Mashiko K, Yamamoto Y: Detection of circulating superantigens in an intensive care unit population. Int J Infect Dis 8(5):292-298, 2004. (Pubitemid 39119853)
26. BrummelhuisWJ, Joles JA, Stam JC, Adams H, Goldschmeding R, Detmers FJ, El Khattabi M, Maassen BT, Verrips CT, Braam B: Llama heavy-chain antibody fragments efficiently remove toxic shock syndrome toxin 1 from plasma in vitro but not in experimental porcine septic shock. Shock 34(2):125-132, 2010.
27. Miwa K, Fukuyama M, Matsuno N, Shimada K, Ikeda K, Ikeda T: Physiological response to superantigen-adsorbing hemoperfusion in toxin- concentrationcontrolled septic swine. Blood Purif 24(3):319-326, 2006. (Pubitemid 43800673)
28. Miwa K, Fukuyama M, Matsuno N, Masuda S, Oyama Y, Ikeda K, Ikeda T: Superantigen-induced multiple organ dysfunction in a toxin- concentrationcontrolled and sequential parameter-monitored swine sepsis model. Int J Infect Dis 10(1):14-24, 2006. (Pubitemid 43003587)
29. Lee PK, Vercellotti GM, Deringer JR, Schlievert PM: Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J Infect Dis 164(4):711-719, 1991.
30. Brosnahan AJ, Schaefers MM, AmundsonWH, Mantz MJ, Squier CA, Peterson ML, Schlievert PM: Novel toxic shock syndrome toxin-1 amino acids required for biological activity. Biochemistry 47(49):12995-13003, 2008.
31. Fujikawa H, Takayama H, Uchiyama T, Igarashi H: Bindings of toxic shock syndrome toxin-1 and staphylococcal enterotoxins A, B, and C to rabbit spleen cells. Microbiol Immunol 33(5): 381-390, 1989. (Pubitemid 19152045)
32. Peterson ML, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, Schlievert PM: The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin. Infect Immun 73(4):2164-2174, 2005. (Pubitemid 40470816)
33. Mourad W, Scholl P, Diaz A, Geha R, Chatila T: The staphylococcal toxic shock syndrome toxin 1 triggers B cell proliferation and differentiation via major histocompatibility complex-unrestricted cognate T/B cell interaction. J Exp Med 170(6):2011-2022, 1989. (Pubitemid 20010081)
34. Hamad AR, Marrack P, Kappler JW: Transcytosis of staphylococcal superantigen toxins. J Exp Med 185(8):1447-1454, 1997. (Pubitemid 27187601)
35. Kushnaryov VM, MacDonald HS, Reiser RF, Bergdoll MS: Reaction of toxic shock syndrome toxin 1 with endothelium of human umbilical cord vein. Rev Infect Dis 11(Suppl 1):S282YS287; discussion S287YS288, 1989.
36. Batisson M, Strazielle N, Hejmadi M, Thomas D, Ghersi-Egea JF, Etienne J, Vandenesch F, Lina G: Toxic shock syndrome toxin-1 challenges the neuroprotective functions of the choroidal epithelium and induces neurotoxicity. J Infect Dis 194(3):341-349, 2006. (Pubitemid 44116976)
37. Cruz DN, Perazella MA, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri VM, et al.: Effectiveness of polymyxin BYimmobilized fiber column in sepsis: a systematic review. Crit Care 11(2): R47, 2007.
38. Grootendorst AF, van Bommel EF, van der Hoven B, van Leengoed LA, van Osta AL: High volume hemofiltration improves right ventricular function in endotoxin-induced shock in the pig. Intensive Care Med 18(4):235-240, 1992.
39. Stein B, Pfenninger E, Grunert A, Schmitz JE, Hudde M: Influence of continuous haemofiltration on haemodynamics and central blood volume in experimental endotoxic shock. Intensive Care Med 16(8):494-499, 1990.
40. Kellum JA, Bellomo R: Hemofiltration in sepsis: where do we go from here? Crit Care 4(2):69-71, 2000. (Pubitemid 30225929)
41. Toft P, Kehler D, Brandslund II, Tonnsen E: The immunological effects of continuous veno-venous haemodiafiltration in critically ill patients. Crit Care 3(6):159-165, 1999. (Pubitemid 30004544)
42. Bellomo R, Tipping P, Boyce N: Tumor necrosis factor clearances during venovenous hemodiafiltration in the critically ill. ASAIO Trans 37(3):M322YM323, 1991.
43. Sander A, Armbruster W, Sander B, Philipp T, Schafer C, Thurauf N, Lange R: The influence of continuous hemofiltration on cytokine elimination and the cardiovascular stability in the early phase of sepsis. Contrib Nephrol 116: 99-103, 1995.
44. Tonnesen E, Hansen MB, Hohndorf K, Diamant M, Bendtzen K, Wanscher M, Toft P: Cytokines in plasma and ultrafiltrate during continuous arteriovenous haemofiltration. Anaesth Intensive Care 21(6):752-758, 1993. (Pubitemid 24000068)
45. Palevsky PM, Zhang JH, O'Connor TZ, Chertow GM, Crowley ST, Choudhury D, Finkel K, Kellum JA, Paganini E, Schein RM, et al.: Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359(1): 7-20, 2008. (Pubitemid 351931092)
46. Payen D, Mateo J, Cavaillon JM, Fraisse F, Floriot C, Vicaut E: Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37(3):803-810, 2009.
47. Boussekey N, Chiche A, Faure K, Devos P, Guery B, d'Escrivan T, Georges H, Leroy O: A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. Intensive Care Med 34(9): 1646-1653, 2008.
48. Cole L, Bellomo R, Journois D, Davenport P, Baldwin I, Tipping P: Highvolume haemofiltration in human septic shock. Intensive Care Med 27(6): 978-986, 2001. (Pubitemid 32662478)
49. Cornejo R, Downey P, Castro R, Romero C, Regueira T, Vega J, Castillo L, Andresen M, Dougnac A, Bugedo G, et al.: High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 32(5): 713-722, 2006.
50. Honore PM, Jamez J, Wauthier M, Lee PA, Dugernier T, Pirenne B, Hanique G, Matson JR: Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Critical Care Med 28(11):3581-3587, 2000.
51. Zhang P, Yang Y, Lv R, Zhang Y, Xie W, Chen JH: Effect of the intensity of continuous renal replacement therapy in patients with sepsis and acute kidney injury: single-center randomized clinical trial. Nephrol Dial Transplant Epub ahead of print Sept 2, 2011.
52. Nakamura M, Oda S, Sadahiro T, Hirayama Y, Watanabe E, Tateishi Y, Nakada TA, Hirasawa H: Treatment of severe sepsis and septic shock by CHDF using a PMMA membrane hemofilter as a cytokine modulator. Contrib Nephrol 166:73-82, 2010.
53. Kohro S, Imaizumi H, Yamakage M, Masuda Y, Namiki A, Asai Y: Reductions in levels of bacterial superantigens/cannabinoids by plasma exchange in a patient with severe toxic shock syndrome. Anaesth Intensive Care 32(4):588-591, 2004. (Pubitemid 39172468)
54. Natanson C, Hoffman WD, Koev LA, Dolan DP, Banks SM, Bacher J, Danner RL, Klein HG, Parrillo JE: Plasma exchange does not improve survival in a canine model of human septic shock. Transfusion 33(3):243-248, 1993. (Pubitemid 23073648)
55. Christensen RD, Anstall HB, Rothstein G: Review: deficiencies in the eutrophils system of newborn infants, and the use of leukocyte transfusions in the treatment of neonatal sepsis. J Clin Apher 1(1):33-41, 1982. (Pubitemid 13016474)
56. van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LF, van der Meer JW: Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15(3):424-430, 1992.
57. Rokke O, Rekvik OP, Revhaug A: Continuous removal of leucocytes during early gram-negative septicemia reduces plasma levels of endotoxin and improves cardiac performance. Scand J Infect Dis 22(1):79-86, 1990. (Pubitemid 20049589)
58. Hagiwara S, Iwasaka H, Hasegawa A, Hidaka S, Uno A, Ueo K, Uchida T, Noguchi T: Filtration leukocytapheresis therapy ameliorates lipopolysaccharideinduced systemic inflammation in a rat model. J Surg Res 171(2):777-782, 2011.
59. Miwa K, Fukuyama M, Ida N, Igarashi H, Uchiyama T: Preparation of a superantigen-adsorbing device and its superantigen removal efficacies in vitro and in vivo. Int J Infect Dis 7(1):21-26, 2003.
60. Poindexter NJ, Schlievert PM: Binding of toxic-shock-syndrome toxin-1 to human peripheral blood mononuclear cells. J Infect Dis 156(1):122-129, 1987. (Pubitemid 17089393)
61. Papageorgiou AC, Brehm RD, Leonidas DD, Tranter HS, Acharya KR: The refined crystal structure of toxic shock syndrome toxin-1 at 2.07. A resolution. J Mol Biol 260(4):553-569, 1996. (Pubitemid 26254243)